Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01169649 · ClinicalTrials.gov registry record · Phase 2
Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
A Phase 2 study of Pancreas and Neuroendocrine, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT01169649 is a Phase 2 study of Pancreas and Neuroendocrine that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 11 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01169649, a Phase 2 study of Pancreas and Neuroendocrine, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test a new drug called MK-2206. This study is a phase II study. In cancer studies, a phase II study is to find out what effects, good and/or bad, a new treatment has against a certain type of cancer. MK-2206 is an oral medication known as a targeted therapy. By attaching to the target, we hope that MK-2206 may stop the cancer cells from further growth and dividing. This study will help find out if MK-2206 is a helpful drug when taken in patients with neuroendocrine tumor.
Conditions Studied
Interventions
- DRUG MK-2206
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2010-07 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01169649
The ClinicalTrials.gov registry entry for NCT01169649 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pancreas appearing as the primary indexed condition, and to 1 intervention - of which MK-2206 is the first listed.
NCT01169649 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01169649 about?
NCT01169649 is a clinical study titled "Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)". The purpose of this study is to test a new drug called MK-2206. This study is a phase II study. In cancer studies, a phase II study is to find out what effects, good and/or bad, a new treatment has against a certain type of cancer. MK-2206 is an oral medication known as a targeted therapy. By attac...
What is the current status of trial NCT01169649?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2010-07. Estimated completion is 2014-02.
What conditions does trial NCT01169649 study?
This clinical trial studies the following conditions: Pancreas, Neuroendocrine.
What interventions are being tested in trial NCT01169649?
The interventions under investigation include: MK-2206 (DRUG).
Who is sponsoring clinical trial NCT01169649?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01169649 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreas
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.